Benign Prostatic Hyperplasia Pharmacotherapy and Incident Ocular Surface Disease: Comparative Risk of Alpha-blockers vs 5-alpha Reductase Inhibitors
Urology
· Elsevier
The publisher did not provide an abstract — full text is available via the link below.
Read at publisher →
Cite
☆
Get new articles on “Urology”
Subscriptions, keyword tracking and favourites — in the Articlium Telegram bot.
Open in Telegram
Citation
✕
ГОСТ
APA
MLA
BibTeX
Benign Prostatic Hyperplasia Pharmacotherapy and Incident Ocular Surface Disease: Comparative Risk of Alpha-blockers vs 5-alpha Reductase Inhibitors. // Urology. – URL: https://www.sciencedirect.com/science/article/pii/S009042952600542X?dgcid=rss_sd_all
Benign Prostatic Hyperplasia Pharmacotherapy and Incident Ocular Surface Disease: Comparative Risk of Alpha-blockers vs 5-alpha Reductase Inhibitors. Urology. https://www.sciencedirect.com/science/article/pii/S009042952600542X?dgcid=rss_sd_all
“Benign Prostatic Hyperplasia Pharmacotherapy and Incident Ocular Surface Disease: Comparative Risk of Alpha-blockers vs 5-alpha Reductase Inhibitors.” Urology.
@article{article71094,
title = {Benign Prostatic Hyperplasia Pharmacotherapy and Incident Ocular Surface Disease: Comparative Risk of Alpha-blockers vs 5-alpha Reductase Inhibitors},
journal = {Urology},
url = {https://www.sciencedirect.com/science/article/pii/S009042952600542X?dgcid=rss_sd_all}
}